Core Viewpoint - XuanZhu Biotech-B (02575) has seen a significant increase in stock price, rising over 11% and reaching a new high of 33.96 HKD, which is more than 190% above its IPO price of 11.6 HKD [1] Company Overview - XuanZhu Biotech is a Chinese biopharmaceutical company backed by Hong Kong-listed company Sihuan Pharmaceutical, with dual research and development systems for small molecule drugs and large molecule biologics [1] - The company has successfully developed four candidate drugs and is actively developing over ten drug assets targeting diseases such as digestive system disorders, tumors, and non-alcoholic fatty liver disease (NASH) [1] Commercial Products - Currently, XuanZhu Biotech has three commercialized products: Annelazole sodium for duodenal ulcers, Pyrotinib for breast cancer, and Dirocitinib for non-small cell lung cancer, which are expected to be approved in 2023 and 2025 [1] Industry Trends - Huafu Securities believes that the Chinese innovative drug sector is experiencing a transformation driven by quantitative changes leading to qualitative changes, with a positive outlook on the industry trend over the next 5-10 years [1] - Factors such as business development overseas, continuous data catalysts, and the ramp-up of new product sales are expected to drive the rise of innovative drugs [1]
轩竹生物-B再涨超11%刷新上市新高 较招股价涨超190%